Daré Bioscience (NASDAQ:DARE – Get Free Report) is projected to issue its quarterly earnings data before the market opens on Monday, March 31st. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $1.00 million for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.
Daré Bioscience Trading Down 0.3 %
Shares of DARE stock opened at $2.88 on Friday. The company’s fifty day simple moving average is $3.07 and its 200-day simple moving average is $3.29. The company has a market cap of $25.06 million, a PE ratio of -4.88 and a beta of 1.38. Daré Bioscience has a 52 week low of $2.67 and a 52 week high of $7.56.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Daré Bioscience in a research note on Tuesday, December 17th.
About Daré Bioscience
Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Featured Stories
- Five stocks we like better than Daré Bioscience
- Why Are Stock Sectors Important to Successful Investing?
- MarketBeat Week in Review – 03/24 – 03/28
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
